Sirnaomics announced that the Company’s management will present its platform technology and discuss the potential utility of RNAi therapeutics at the 4th Annual Oligonucleotide & Precision Therapeutics: Discovery, Development and Delivery conference on March 25-28, 2019 in Cambridge, Massachusetts.
Sirnaomics announced that the Company will present preclinical data from the use of its RNAi technology program in a liver cancer mouse model at AsiaTIDES: Ogligonucleotide & Peptide Therapeutics taking place in Tokyo, Japan on February 28 – March 1, 2019.
Sirnaomics announced that the management will present and conduct face-to-face meetings at the 2019 BIO CEO & Investor Conference, to be held in New York, NY on February 11-12.
Sirnaomics’ president and CEO Dr. Patrick Lu presents at the CTIC Healthcare Summit on Jan. 6th, 2019, before the 37th JP Morgan Healthcare Conference in San Francisco.
Sirnaomics announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company’s proposed trial design for a Phase 2 clinical study to evaluate its lead product candidate, STP705, for the treatment of in situ Squamous Cell Carcinoma Nonmelanoma Skin Cancer (NMSC).